{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092535","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.320877+00:00","generated_at":"2026-05-15T19:49:11.211909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tango Therapeutics reports Q4 net loss $38.7M, cash $343M; vopimetostat pivotal study on track for 2026","bullets":["Net loss $38.7M for Q4 2025 ($0.29/share) vs $30.8M for Q4 2024; FY2025 net loss $101.6M vs $130.3M.","Cash, equivalents and marketable securities $343.1M as of Dec 31, 2025; runway into 2028.","Collaboration revenue $62.4M for FY2025, including full recognition of remaining Gilead deferred revenue after collaboration truncation.","Vopimetostat pivotal study in 2L MTAP-del pancreatic cancer to start in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026.","Signed clinical supply agreement with Erasca for vopimetostat + pan-RAS molecular glue ERAS-0015; CEO succeeded by Malte Peters in January 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092535","json":"https://secwatch.observer/filing/0001193125-26-092535.json","markdown":"https://secwatch.observer/filing/0001193125-26-092535.md","text":"https://secwatch.observer/filing/0001193125-26-092535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/0001193125-26-092535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/tngx-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:49:11.211909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}